Director, Global Value and Health Economics and Outcomes Research at Jazz Pharmaceuticals in Home-Based, PA

Job description

If you are a current Jazz employee please apply via the Internal Career site Jazz Pharmaceuticals is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information. Job Description The Director, Global Value and HEOR is a strategic and execution-oriented leadership role accountable for the global and US payer evidence strategy across marketed assets in Jazz’ neurology portfolio. This role is responsible for maximizing brand potential, defending value, securing expanded access, and driving evidence generation across the post-launch lifecycle—including label expansions (sNDA/sBLA), new formulations, line extensions, and competitive market shifts. Operating across both broad commercial disease areas and high-uncertainty rare diseases, the Director serves as the strategic evidence engine substantiating the evolving product value story developed by the Market Access team. As a vital stakeholder in the Integrated Evidence Generation Plan (IEGP) governance and brand strategy forums, this role translates commercial, access, and policy priorities into methodologically sound evidence generation plans and tangible deliverables—including updated global core economic models, real-world observational studies, patient registries, Global Value Dossiers (GVDs), and US AMCP dossiers. The Director carries a dual global and regional leadership mandate: serving as the dedicated US HEOR lead (partnering directly with US Market Access, Pricing & Contracting, US Medical Affairs, and the Payer Field Team) while collaborating seamlessly with the EU/INT HEOR team to co-create HTA re-assessment strategies and deliver post-launch evidence packages. ​​Essential Functions/Responsibilities ​1. Lifecycle Management (LCM), Label Expansions & Indication Sequencing ​Evidence Strategy for Label Expansions: Lead the HEOR evidence generation strategy supporting supplemental regulatory filings (sNDA/sBLA) for new indications, line extensions, expanded patient subpopulations, and novel delivery formulations/devices. ​Phase 3b/4 Trial & Pragmatic Study Optimization: Partner closely with Medical Affairs, Clinical Development, and Biostatistics to embed payer-relevant comparative endpoints, patient-reported outcomes (PROs), and health-related quality of life (HRQoL) measures into Phase 3b/4 protocols, pragmatic trials, and expanded access programs. ​Indication Sequencing & Access Strategy: Partner with Market Access to evaluate evidence requirements across multi-indication lifecycles, ensuring timely delivery of comparative effectiveness and economic evidence to accelerate access upon label expansion. ​Rare Disease Registry & Long-Term Follow-Up: For rare disease inline assets, collaborate on long-term prospective registries, natural history extensions, and post-authorization safety/efficacy studies (PASS/PAES) to address regulatory/HTA commitments, characterize disease progression, and mitigate data uncertainty associated with small cohorts. ​2. Inline Value Defense, HTA Re-Assessments & Evidence Optimization ​Value Defense Against Market Entrants: Proactively identify competitive threats, standard-of-care shifts, and generic/biosimilar erosion; design and execute rapid-response comparative effectiveness